Cinclus Pharma (CINPHA) investor relations material

Executive summary

• Linaprazan glurate, a next-generation PCAB, targets severe erosive GERD with unique 24-hour acid control, addressing a large, underserved patient population of 10 million in the US and Europe.

• Phase III HEEALING1 study completed enrollment with 523 patients, exceeding the protocol target; topline results expected in Q4 2026.

• Commercial strategy leverages partnerships with Zentiva (Europe) and Sinorda (Asia/China), with the first global launch in China and strong patent protection.

• Licensing deals with Zentiva (EUR 220m value) and Sinorda provide commercial pathways and upfront revenue.

• Linaprazan glurate demonstrated superior acid control and healing rates compared to PPIs and other PCABs.

Financial highlights

• Q2 2026 cash balance was SEK 388 million, including structured and convertible financing agreements.

• Net sales for Q2 2026 were SEK 1.8 million, mainly from licensing revenue; down from SEK 34.1 million in Q2 2025 due to periodization of the Zentiva deal.

• Operating expenses reached SEK 96 million in Q2 2026, with R&D accounting for 89% of the cost base.

• EBIT for Q2 2026 was SEK -95 million, reflecting high R&D spend for phase III execution.

• Net loss for Q2 2026 was SEK -78.8 million.

Outlook and guidance

• Topline results from HEEALING1 expected in Q4 2026; HEEALING2 to initiate soon after, with preparations underway.

• Cash runway extends into Q3 2027, covering all HEEALING1 costs and some HEEALING2 preparations.

• Additional financing will be needed for HEEALING2 and regulatory submissions.

• Q3 and Q4 results to be reported on November 11, 2026, and February 17, 2027, respectively.

• Focus remains on clinical execution, regulatory progress, and leveraging licensing partnerships.